Rocbrutinib plus R-CHOP yielded a 100% ORR and an 86.7% CR rate in 15 patients with untreated non-GCB DLBCL, warranting randomized evaluation.
|Articles|October 7, 2008
Hematological Malignancies: Current Perspectives on Diagnosis, Prognosis, and Treatment.
This supplement to ONCOLOGY provides a comprehensive look at state-of-the-art management of three of the most prevalent hematological malignancies in the US today.
Advertisement
This supplement to ONCOLOGY provides a comprehensive look at state-of-the-art management of three of the most prevalent hematological malignancies in the US today: chronic lymphocytic leukemia, non-Hodgkin lymphoma, and acute myeloid leukemia. This supplement is supported by an educational grant from Cephalon Oncology, and is jointly sponsored by Postgraduate Institute for Medicine and Vital Issues in Medicine. CME/PE/CE credit is available.
Advertisement
Related to this article
Grade 3/4 neurotoxicity in patients prompted a partial clinical hold on the PALISADES-1 and PALISADES-2 trials of KITE-753 in large B-cell lymphoma.
In a phase 2 trial, orelabrutinib plus sintilimab yielded a 60.7% overall response rate in relapsed/refractory primary CNS lymphoma.
Oral vitamin C improved OS in patients with CCUS or lower-risk myeloid malignancies in the EVITA trial despite missing the clonal growth primary end point.
Advertisement
Advertisement
Trending on CancerNetwork
1
AI-Measured Tumor Volume on PSMA PET-CT Linked With Survival in Prostate Cancer
2
KITE-753 Trials in R/R DLBCL Placed on Partial Clinical Hold for ICANS
3
How Could Rocbrutinib Plus R-CHOP Reshape Frontline Non-GCB DLBCL Treatment?
4
Managing FLOT Toxicity With Dose Reductions in Gastroesophageal Cancer
5